Cited by 1,559Prostate Cancer Treatment and ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

Open access
Gao, Dong, Vela, Ian, Sboner, Andrea, Iaquinta, Phillip J., Karthaus, Wouter R., Gopalan, Anuradha, Dowling, Catherine, Wanjala, Jackline N. +31 more·2014·Cell

Abstract

The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate cancer has hampered progress in understanding disease pathogenesis and therapy response. Using a 3D organoid system, we report success in long-term culture of prostate cancer from biopsy specimens and circulating tumor cells. The first seven fully characterized organoid lines recapitulate the molecular diversity of prostate cancer subtypes, including TMPRSS2-ERG fusion, SPOP mutation, SPINK1 overexpression, and CHD1 loss. Whole-exome sequencing shows a low mutational burden, consistent with genomics studies, but with mutations in FOXA1 and PIK3R1, as well as in DNA repair and chromatin modifier pathways that have been reported in advanced disease. Loss of p53 and RB tumor suppressor pathway function are the most common feature shared across the organoid lines. The methodology described here should enable the generation of a large repertoire of patient-derived prostate cancer lines amenable to genetic and pharmacologic studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2014.08.016

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tumor tissue from biopsies or surgical resections is typically processed similarly to normal tissue to isolate tumor cells for organoid growth.

    “Tumor tissue, derived from either biopsies or surgical resections, is also typically processed akin to normal tissue to isolate tumour cells to grow as organoids16,49–51.”

    From Organoids (2022) · cites this paper as [51]

    The Experimental Procedures section describes mincing and digesting metastatic prostate cancer biopsy pieces, then seeding the dissociated cells in Matrigel for organoid growth (page not provided). The paper says it used growth conditions developed for normal prostate epithelial cells, but does not establish that tumor tissue was processed like normal tissue, that surgical resections were used, or that this was typical practice. The Results also note that selectively isolating tumor cells from other biopsy cells remained a proposed improvement. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., Wongvipat, J., Kossai, M., Ramazanoglu, S., Barboza, L. P., Di, W., Cao, Z., Zhang, Q. F., Sirota, I., Ran, L., MacDonald, T. Y., Beltran, H., Mosquera, J.-M., Touijer, K. A., Scardino, P. T., Laudone, V. P., Curtis, K. R., Rathkopf, D. E., Morris, M. J., Danila, D. C., Slovin, S. F., Solomon, S. B., Eastham, J. A., Chi, P., Carver, B., Rubin, M. A., Scher, H. I., Clevers, H., Sawyers, C. L., & Chen, Y.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • NewYork–Presbyterian Hospital (US)
  • Royal Netherlands Academy of Arts and Sciences (NL)
Corresponding author
  • Sawyers, Charles L.
  • Chen, Yu
Venue
Cell
Publisher
Elsevier BV
Published
2014-09
Volume
159
Issue
1
Pages
176-187
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2059586354
Cited by
1,559
References
50
Citations by year
2026: 110 · 2025: 117 · 2024: 138 · 2023: 145 · 2022: 155 · 2021: 172 · 2020: 180 · 2019: 131 · 2018: 131 · 2017: 120 · 2016: 87 · 2015: 67 · 2014: 5
FWCI
73.95
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • QUT ePrints (Queensland University of Technology) (submittedVersion)
  • NSUWorks (Nova Southeastern University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion)
Funders
  • U.S. Department of Defense (W81XWH, W81XWH1010197)
  • American Association for Cancer Research (SU2C-AACR-DT0712)
  • Prostate Cancer Foundation (SU2C-AACR-DT0712)
  • Memorial Sloan-Kettering Cancer Center (P50CA092629)
  • Movember Foundation
  • National Institutes of Health (W81XWH, UL1TR000457)
  • Stand Up To Cancer (SU2C-AACR-DT0712)
  • National Cancer Institute (R01CA182503, K08CA151660, R01CA116337, CA155169-01A1, K08CA140946, R01CA155169, P30CA008748, P50CA092629, R01CA193837)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
prostate cancer, organoids, circulating tumor cells, 3D organoid culture, TMPRSS2-ERG fusion, SPOP mutations, FOXA1, PIK3R1, DNA repair mutations, p53 deficiency, mutational burden, advanced prostate cancer
MeSH terms
Humans, Male, Neoplasm Metastasis, Organoids, Pharmacology, Prostatic Neoplasms, Tumor Suppressor Proteins, Culture Techniques, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review